McKinsey’s Ulf Schrader on Toyota and Quality Lessons for Pharma
Design to Quality...presents industry with a $20-to-$30-billion opportunity to optimize technical development. And that’s just on the cost side, without even considering the customer preference angle....
View ArticleBikash Chatterjee With Lessons From Toyota
"The key to excellence in operational excellence or product development is knowledge management, which ensures that lessons learned from one product, one process, or one initiative are available and...
View ArticleTunnell’s Robert Spector With Lessons for Pharma from Toyota
Pharma's inventory turns remain among the lowest of all manufacturing industries says Spector.
View ArticleAllies in Lean Six Sigma: What Lilly and Covance Have Learned
As drug development partners, Lilly and Covance have learned from joint Lean Six Sigma projects, explains Lilly Black Belt Dan Rudmann.
View ArticleSix Sigma in Drug Development at Covance: The Good, Bad, and Ugly
At DIA 2010 in Washington, DC, Master Black Belt Michael Walega talked about best practices, and bad practices and overcoming rampant excuses.
View ArticleA QbD Summer Reading List
For QbD-philes, a reading list of summer articles to tote to the beach or office.
View ArticleLean Upstream: Catalyzing Pharma Product Development
How much more can pharma extract from shop-floor processes and remain competitive? It's time to apply Lean further upstream, says Pharmatech's Bikash Chatterjee.
View ArticleAre You Cutting Corners on Your Lean Lab Journey?
Lean implementation in QC and other labs requires real cultural and paradigm change, say BSM's Lorcan Mannion and Pfizer's Ciaran Crosbie. There can be no shortcuts.
View ArticleDoes Lean Six Sigma Enhance or Stifle Innovation in Drug R&D?
A trio of authors from AstraZeneca R&D tackle this question, concluding that corporate climate is the critical factor regarding the success or failure of continuous improvement efforts in drug...
View ArticleCutting Through the QbD Foliage, Aiming for the Roots
It is not enough to optimize the existing paradigm of mass production that exists in Pharma, says consultant Hedley Rees.
View Article
